Search research articles
Contact Us
Filters
Showing results (161-170 of 235) with videos related to
Page
of 24
Sort By:
Journal for Immunotherapy of Cancer
|
July 18, 2018
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
Julie R Brahmer, Ramaswamy Govindan, Robert A Anders, et al.
The New England Journal of Medicine
|
April 17, 2018
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Matthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.
Nature Cancer
|
August 29, 2022
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer
Rami S Vanguri, Jia Luo, Andrew T Aukerman, et al.
Science (New York, N.Y.)
|
March 14, 2015
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, et al.
British Journal of Cancer
|
December 29, 2021
Immune biomarkers and response to checkpoint inhibition of BRAF<sup>V600</sup> and BRAF non-V600 altered lung cancers
Yonina R Murciano-Goroff, Terry Pak, Sebastian Mondaca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2019
Treatment Outcomes of Immune-Related Cutaneous Adverse Events
Gregory S Phillips, Jennifer Wu, Matthew D Hellmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 5, 2019
Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis
Ila Datar, Miguel F Sanmamed, Jun Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 17, 2019
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Kyung Hae Jung, Patricia LoRusso, Howard Burris, et al.
Nature Medicine
|
July 10, 2023
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results
Martin Gutierrez, Wei-Sen Lam, Matthew D Hellmann, et al.
Nature
|
June 18, 2019
TOX is a critical regulator of tumour-specific T cell differentiation
Andrew C Scott, Friederike Dündar, Paul Zumbo, et al.
Page
of 24
Search research articles
Search
Showing results (161-170 of 235) with videos related to
Sort By:
Page
of 24
Journal for Immunotherapy of Cancer
|
July 18, 2018
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
Julie R Brahmer, Ramaswamy Govindan, Robert A Anders, et al.
The New England Journal of Medicine
|
April 17, 2018
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Matthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.
Nature Cancer
|
August 29, 2022
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer
Rami S Vanguri, Jia Luo, Andrew T Aukerman, et al.
Science (New York, N.Y.)
|
March 14, 2015
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, et al.
British Journal of Cancer
|
December 29, 2021
Immune biomarkers and response to checkpoint inhibition of BRAF<sup>V600</sup> and BRAF non-V600 altered lung cancers
Yonina R Murciano-Goroff, Terry Pak, Sebastian Mondaca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2019
Treatment Outcomes of Immune-Related Cutaneous Adverse Events
Gregory S Phillips, Jennifer Wu, Matthew D Hellmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 5, 2019
Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis
Ila Datar, Miguel F Sanmamed, Jun Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 17, 2019
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Kyung Hae Jung, Patricia LoRusso, Howard Burris, et al.
Nature Medicine
|
July 10, 2023
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results
Martin Gutierrez, Wei-Sen Lam, Matthew D Hellmann, et al.
Nature
|
June 18, 2019
TOX is a critical regulator of tumour-specific T cell differentiation
Andrew C Scott, Friederike Dündar, Paul Zumbo, et al.
Page
of 24